S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL

• Nigel Russell,
• Jad Othman,
• Richard Dillon,
• Nicola Potter,
• Charlotte Wilhelm-Benartzi,
• Steven Knapper,
• Leona Batten,
• Joanna Canham,
• Emily Laura Hinson,
• Ulrik Malthe Overgaard,
• Amanda Gilkes,
• Priyanka Mehta,
• Panagiotis Kottaridis,
• Jamie Cavenagh,
• Claire Hemmaway,
• Claire Arnold,
• Sylvie Freeman,
• Mike Dennis

Affiliations

Nigel Russell

1 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

Jad Othman

2 Kings College London, Department of Medical and Molecular Genetics, London, United Kingdom

Richard Dillon

2 Kings College London, Department of Medical and Molecular Genetics, London, United Kingdom

Nicola Potter

2 Kings College London, Department of Medical and Molecular Genetics, London, United Kingdom

Charlotte Wilhelm-Benartzi

3 Cardiff University, Centre for Trials Research, Cardiff, United Kingdom

Steven Knapper

4 Cardiff University, School of Medicine, Cardiff, United Kingdom

Leona Batten

3 Cardiff University, Centre for Trials Research, Cardiff, United Kingdom

Joanna Canham

3 Cardiff University, Centre for Trials Research, Cardiff, United Kingdom

Emily Laura Hinson

3 Cardiff University, Centre for Trials Research, Cardiff, United Kingdom

Ulrik Malthe Overgaard

5 Copenhagen University Hospital, Copenhagen, Denmark

Amanda Gilkes

4 Cardiff University, School of Medicine, Cardiff, United Kingdom

Priyanka Mehta

6 University Hospitals of Bristol and Weston NHS Trust, Bristol, United Kingdom

Panagiotis Kottaridis

7 University College London Hospitals NHS Foundation Trust, London, United Kingdom

Jamie Cavenagh

8 St Bartholomew’s Hospital, Department of Haematology, London, United Kingdom

Claire Hemmaway

9 Auckland Hospital, Auckland, Australia

Claire Arnold

10 Belfast City Hospital, Belfast, United Kingdom

Sylvie Freeman

11 University of Birmingham, Institute of Immunology and Immunotherapy, Birmingham, United Kingdom

Mike Dennis

12 The Christie NHS Foundation Trust, On behalf of the UK NCRI AML Working Group, Manchester, United Kingdom